Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients

Launched by UNIVERSITY OF BERN · Jul 16, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option called Eurythmy therapy (ERYT) to help reduce fatigue in women with metastatic breast cancer. Fatigue related to cancer can be very overwhelming and affects more than 75% of patients with advanced breast cancer, significantly impacting their daily lives and well-being. The study aims to see if ERYT, which combines mindful movement exercises, is more effective than a standard movement program (CoordiFit) in alleviating this fatigue over a 20-week period. Participants will attend 13 therapy sessions, each lasting 45 minutes, and will be monitored for improvements in fatigue, quality of life, sleep, anxiety, and other factors.

To be eligible for this trial, participants must be women aged 18 or older with confirmed metastatic breast cancer who experience significant fatigue. They should be able to engage in physical activities and speak one of the study's languages (German, French, or Italian). However, certain health conditions, such as serious heart problems or psychiatric disorders, may prevent someone from participating. If the study finds that ERYT is beneficial, it could lead to better treatment options not just for breast cancer patients, but for others with cancer-related fatigue as well.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female, aged 18 years or older
• • Histologically or cytologically confirmed metastatic breast cancer
• • FACIT-F subscale score \< 34 (considered as cut-off for a diagnosis of relevant fatigue; a score \< 30 is considered as severe fatigue \[83\])
• • Eastern Cooperative Oncology Group (ECOG) grade 1 or 2
• • Ability to physically and cognitively perform an active movement therapy
• • Ability to provide informed consent as documented by signature
• • Ability to read, write, and speak German, French, or Italian
• Exclusion Criteria:
• • Inability or contraindication that would prevent prolonged follow-up, or to undergo the investigated intervention or control intervention, in the opinion of the investigator
• • Patients with psychiatric, addictive or any disorder that prevents the patient from adhering to the protocol requirements, in the opinion of the investigator
• • Significant uncontrolled cardiac disease (e.g. unstable angina, recent myocardial infarction)
• • Haemoglobin \< 90 g/L